Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 649396, 10 pages
http://dx.doi.org/10.1155/2013/649396
Review Article

Diabetes Cognitive Impairments and the Effect of Traditional Chinese Herbs

Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China

Received 20 June 2013; Revised 15 November 2013; Accepted 19 November 2013

Academic Editor: I-Min Liu

Copyright © 2013 Xiaohan Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Yang, J. Lu, J. Weng et al., “Prevalence of diabetes among men and women in China,” New England Journal of Medicine, vol. 362, no. 25, p. 2425, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Zhao, W. Ye, K. S. Boye, J. H. Holcombe, J. A. Hall, and R. Swindle, “Prevalence of other diabetes-associated complications and comorbidities and its impact on health care charges among patients with diabetic neuropathy,” Journal of Diabetes and Its Complications, vol. 24, no. 1, pp. 9–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. E. J. Schoenle, D. Schoenle, L. Molinari, and R. H. Largo, “Impaired intellectual development in children with type I diabetes: association with hba1c, age at diagnosis and sex,” Diabetologia, vol. 45, no. 1, pp. 108–114, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. S. C. Ferguson, A. Blane, P. Perros et al., “Cognitive ability and brain structure in type 1 diabetes: relation to microangiopathy and preceding severe hypoglycemia,” Diabetes, vol. 52, no. 1, pp. 149–156, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. A. M. A. Brands, E. Van Den Berg, S. M. Manschot et al., “A detailed profile of cognitive dysfunction and its relation to psychological distress in patients with type 2 diabetes mellitus,” Journal of the International Neuropsychological Society, vol. 13, no. 2, pp. 288–297, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. Å. Wahlin, E. Nilsson, and J. Fastbom, “Cognitive performance in very old diabetic persons: the impact of semantic structure, preclinical dementia, and impending death,” Neuropsychology, vol. 16, no. 2, pp. 208–216, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. G. J. Biessels, S. Staekenborg, E. Brunner, C. Brayne, and P. Scheltens, “Risk of dementia in diabetes mellitus: a systematic review,” The Lancet Neurology, vol. 5, no. 1, pp. 64–74, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. D. Reijmer, E. van den Berg, C. Ruis, L. J. Kappelle, and G. J. Biessels, “Cognitive dysfunction in patients with type 2 diabetes,” Diabetes-Metabolism Research and Reviews, vol. 26, no. 7, pp. 507–519, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. A. M. Patiño-Fernández, A. M. Delamater, E. B. Applegate et al., “Neurocognitive functioning in preschool-age children with type 1 diabetes mellitus,” Pediatric Diabetes, vol. 11, no. 6, pp. 424–430, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. G.-J. Biessels, A. Kamal, G. M. Ramakers et al., “Place learning and hippocampal synaptic plasticity in streptozotocin- induced diabetic rats,” Diabetes, vol. 45, no. 9, pp. 1259–1266, 1996. View at Google Scholar · View at Scopus
  11. B. Van Harten, J. Oosterman, D. Muslimovic, B.-J. P. van Loon, P. Scheltens, and H. C. Weinstein, “Cognitive impairment and MRI correlates in the elderly patients with type 2 diabetes mellitus,” Age and Ageing, vol. 36, no. 2, pp. 164–170, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. S. A. Ebady, M. A. Arami, and M. H. Shafigh, “Investigation on the relationship between diabetes mellitus type 2 and cognitive impairment,” Diabetes Research and Clinical Practice, vol. 82, no. 3, pp. 305–309, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Munshi, L. Grande, M. Hayes et al., “Cognitive dysfunction is associated with poor diabetes control in older adults,” Diabetes Care, vol. 29, no. 8, pp. 1794–1799, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. A. M. Kanaya, E. Barrett-Connor, G. Gildengorin, and K. Yaffe, “Change in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo Study cohort,” Archives of Internal Medicine, vol. 164, no. 12, pp. 1327–1333, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Maggi, F. Limongi, M. Noale et al., “Diabetes as a risk factor for cognitive decline in older patients,” Dementia and Geriatric Cognitive Disorders, vol. 27, no. 1, pp. 24–33, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Logroscino, J. H. Kang, and F. Grodstein, “Prospective study of type 2 diabetes and cognitive decline in women aged 70–81 years,” British Medical Journal, vol. 328, no. 7439, pp. 548–551, 2004. View at Google Scholar · View at Scopus
  17. D. J. Cox, B. P. Kovatchev, L. A. Gonder-Frederick et al., “Relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes,” Diabetes Care, vol. 28, no. 1, pp. 71–77, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. W. L. Xu, E. Von Strauss, C. X. Qiu, B. Winblad, and L. Fratiglioni, “Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study,” Diabetologia, vol. 52, no. 6, pp. 1031–1039, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. D. G. Bruce, W. A. Davis, G. P. Casey et al., “Predictors of cognitive impairment and dementia in older people with diabetes,” Diabetologia, vol. 51, no. 2, pp. 241–248, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. A. M. Wessels, P. Scheltens, F. Barkhof, and R. J. Heine, “Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetes,” European Journal of Pharmacology, vol. 585, no. 1, pp. 88–96, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Fukui, N.-O. Omoi, T. Hayasaka et al., “Cognitive impairment of rats caused by oxidative stress and aging, and its prevention by vitamin E,” Annals of the New York Academy of Sciences, vol. 959, pp. 275–284, 2002. View at Google Scholar · View at Scopus
  22. D. Comin, L. Gazarini, J. N. Zanoni, H. Milani, and R. M. W. de Oliveira, “Vitamin E improves learning performance and changes the expression of nitric oxide-producing neurons in the brains of diabetic rats,” Behavioural Brain Research, vol. 210, no. 1, pp. 38–45, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Kuhad and K. Chopra, “Effect of sesamol on diabetes-associated cognitive decline in rats,” Experimental Brain Research, vol. 185, no. 3, pp. 411–420, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. S. K. Srivastava, K. V. Ramana, and A. Bhatnagar, “Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options,” Endocrine Reviews, vol. 26, no. 3, pp. 380–392, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. M. A. Malone, D. D. Schocken, S. K. Hanna, X. Liang, and J. I. Malone, “Diabetes-induced bradycardia is an intrinsic metabolic defect reversed by carnitine,” Metabolism, vol. 56, no. 8, pp. 1118–1123, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Wright Jr., J. L. Scism-Bacon, and L. C. Glass, “Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia,” International Journal of Clinical Practice, vol. 60, no. 3, pp. 308–314, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. F. K. Ahmad, Z. He, and G. L. King, “Molecular targets of diabetic cardiovascular complications,” Current Drug Targets, vol. 6, no. 4, pp. 487–494, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Toth, A. M. Schmidt, U. I. Tuor et al., “Diabetes, leukoencephalopathy and rage,” Neurobiology of Disease, vol. 23, no. 2, pp. 445–461, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Ramakrishnan, R. Sheeladevi, and N. Suthanthirarajan, “PKC-α mediated alterations of indoleamine contents in diabetic rat brain,” Brain Research Bulletin, vol. 64, no. 2, pp. 189–194, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Aragno, R. Mastrocola, C. Medana et al., “Up-regulation of advanced glycated products receptors in the brain of diabetic rats is prevented by antioxidant treatment,” Endocrinology, vol. 146, no. 12, pp. 5561–5567, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. L. J. Launer, M. E. Miller, J. D. Williamson et al., “Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy,” The Lancet Neurology, vol. 10, no. 11, pp. 969–977, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. W. T. Friedewald, J. B. Buse, J. T. Bigger et al., “Effects of intensive glucose lowering in type 2 diabetes,” New England Journal of Medicine, vol. 358, no. 24, pp. 2545–2559, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. W. Duckworth, C. Abraira, T. Moritz et al., “Glucose control and vascular complications in veterans with type 2 diabetes,” New England Journal of Medicine, vol. 360, no. 2, pp. 129–139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Patel, S. MacMahon, J. Chalmers et al., “Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes,” New England Journal of Medicine, vol. 358, no. 24, pp. 2560–2572, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. R. N. Auer, “Hypoglycemic brain damage,” Metabolic Brain Disease, vol. 19, no. 3-4, pp. 169–175, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. V. McAulay, I. J. Deary, and B. M. Frier, “Symptoms of hypoglycaemia in people with diabetes,” Diabetic Medicine, vol. 18, no. 9, pp. 690–705, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. R. A. Whitmer, A. J. Karter, K. Yaffe, C. P. Quesenberry Jr., and J. V. Selby, “Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus,” Journal of the American Medical Association, vol. 301, no. 15, pp. 1565–1572, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Hershey, S. Craft, N. Bhargava, and N. H. White, “Memory and insulin dependent diabetes mellitus (IDDM): effects of childhood onset and severe hypoglycemia,” Journal of the International Neuropsychological Society, vol. 3, no. 6, pp. 509–520, 1997. View at Google Scholar · View at Scopus
  40. A. M. Jacobson, G. Musen, C. M. Ryan et al., “For the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Long-term effect of diabetes and its treatment on cognitive function,” N Engl J Med, vol. 356, no. 18, pp. 1842–1852, 2007. View at Google Scholar
  41. A. M. A. Brands, G. J. Biessels, E. H. F. De Haan, L. J. Kappelle, and R. P. C. Kessels, “The effects of type 1 diabetes on cognitive performance: a meta-analysis,” Diabetes Care, vol. 28, no. 3, pp. 726–735, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. D. G. Bruce, W. A. Davis, G. P. Casey et al., “Severe hypoglycaemia and cognitive impairment in older patients with diabetes. The Fremantle Diabetes Study,” Diabetologia, vol. 52, no. 9, pp. 1808–1815, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. R. E. Warren and B. M. Frier, “Hypoglycaemia and cognitive function,” Diabetes, Obesity and Metabolism, vol. 7, no. 5, pp. 493–503, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. G. J. Biessels, “Hypoglycemia and dementia in type 2 diabetes: chick or egg?” Nature Reviews Endocrinology, vol. 5, no. 10, pp. 532–534, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Aye, A. L. Reiss, S. Kesler et al., “The feasibility of detecting neuropsychologic and neuroanatomic effects of type 1 diabetes in young children,” Diabetes Care, vol. 34, no. 7, pp. 1458–1462, 2011. View at Google Scholar · View at Scopus
  46. B. O. Åsvold, T. Sand, K. Hestad, and M. R. Bjørgaas, “Cognitive function in type 1 diabetic adults with early exposure to severe hypoglycemia: a 16-year follow-up study,” Diabetes Care, vol. 33, no. 9, pp. 1945–1947, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. W. A. Banks, “The source of cerebral insulin,” European Journal of Pharmacology, vol. 490, no. 1–3, pp. 5–12, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Gerozissis, “Brain insulin and feeding: a bi-directional communication,” European Journal of Pharmacology, vol. 490, no. 1–3, pp. 59–70, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. W.-Q. Zhao and D. L. Alkon, “Role of insulin and insulin receptor in learning and memory,” Molecular and Cellular Endocrinology, vol. 177, no. 1-2, pp. 125–134, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. E. Steen, B. M. Terry, E. J. Rivera et al., “Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease—is this type 3 diabetes?” Journal of Alzheimer's Disease, vol. 7, no. 1, pp. 63–80, 2005. View at Google Scholar · View at Scopus
  51. S. M. De La Monte and J. R. Wands, “Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 7, no. 1, pp. 45–61, 2005. View at Google Scholar · View at Scopus
  52. S. E. Young, A. G. Mainous III, and M. Carnemolla, “Hyperinsulinemia and cognitive decline in a middle-aged cohort,” Diabetes Care, vol. 29, no. 12, pp. 2688–2693, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. R. V. Bhat, J. Shanley, M. P. Correll et al., “Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3β in cellular and animal models of neuronal degeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 20, pp. 11074–11079, 2000. View at Google Scholar · View at Scopus
  54. C. J. Phiel, C. A. Wilson, V. M.-Y. Lee, and P. S. Klein, “GSK-3α regulates production of Alzheimer's disease amyloid-β peptides,” Nature, vol. 423, no. 6938, pp. 435–439, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. W. Farris, S. Mansourian, Y. Chang et al., “Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 4162–4167, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. W. Q. Qiu, D. M. Walsh, Z. Ye et al., “Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation,” Journal of Biological Chemistry, vol. 273, no. 49, pp. 32730–32738, 1998. View at Publisher · View at Google Scholar · View at Scopus
  57. P. K. Elias, M. F. Elias, R. B. D'Agostino et al., “NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study,” Diabetes Care, vol. 20, no. 9, pp. 1388–1395, 1997. View at Google Scholar · View at Scopus
  58. E. Van Den Berg, J. M. Dekker, G. Nijpels et al., “Blood pressure levels in pre-diabetic stages are associated with worse cognitive functioning in patients with type 2 diabetes,” Diabetes/Metabolism Research and Reviews, vol. 25, no. 7, pp. 657–664, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Bruehl, O. T. Wolf, V. Sweat, A. Tirsi, S. Richardson, and A. Convit, “Modifiers of cognitive function and brain structure in middle-aged and elderly individuals with type 2 diabetes mellitus,” Brain Research, vol. 1280, pp. 186–194, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. S. M. Manschot, G. J. Biessels, H. De Valk et al., “Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes,” Diabetologia, vol. 50, no. 11, pp. 2388–2397, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Ruitenberg, I. Skoog, A. Ott et al., “Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 study,” Dementia and Geriatric Cognitive Disorders, vol. 12, no. 1, pp. 33–39, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. M. M. Mielke, P. P. Zandi, M. Sjögren et al., “High total cholesterol levels in late life associated with a reduced risk of dementia,” Neurology, vol. 64, no. 10, pp. 1689–1695, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. R. P. Kloppenborg, E. van den Berg, L. J. Kappelle, and G. J. Biessels, “Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review,” European Journal of Pharmacology, vol. 585, no. 1, pp. 97–108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. J. A. Luchsinger, M.-X. Tang, Y. Stern, S. Shea, and R. Mayeux, “Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort,” American Journal of Epidemiology, vol. 154, no. 7, pp. 635–641, 2001. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Alter, S.-M. Lai, G. Friday, V. Singh, V. Mangesh Kumar, and E. Sobel, “Stroke recurrence in diabetics: does control of blood glucose reduce risk?” Stroke, vol. 28, no. 6, pp. 1153–1157, 1997. View at Google Scholar · View at Scopus
  66. G. Rodriguez, F. Nobili, M. A. Celestino et al., “Regional cerebral blood flow and cerebrovascular reactivity in IDDM,” Diabetes Care, vol. 16, no. 2, pp. 462–468, 1993. View at Google Scholar · View at Scopus
  67. P. C. Johnson, K. Brendel, and E. Meezan, “Thickened cerebral cortical capillary basement membranes in diabetes,” Archives of Pathology and Laboratory Medicine, vol. 106, no. 5, pp. 214–217, 1982. View at Google Scholar · View at Scopus
  68. M. Yngen, C.-G. Östenson, H. Hu, N. Li, P. Hjemdahl, and N. H. Wallén, “Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with Type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation,” Diabetologia, vol. 47, no. 3, pp. 537–540, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Dalla Vestra, M. Mussap, P. Gallina et al., “Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes,” Journal of the American Society of Nephrology, vol. 16, no. 3, pp. S78–S82, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. M. T. Schram, N. Chaturvedi, C. G. Schalkwijk, J. H. Fuller, and C. D. A. Stehouwer, “Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB Prospective Complications Study,” Diabetologia, vol. 48, no. 2, pp. 370–378, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. L. P. Reagan, C. A. Grillo, and G. G. Piroli, “The As and Ds of stress: metabolic, morphological and behavioral consequences,” European Journal of Pharmacology, vol. 585, no. 1, pp. 64–75, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. A. M. Stranahan, T. V. Arumugam, R. G. Cutler, K. Lee, J. M. Egan, and M. P. Mattson, “Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons,” Nature Neuroscience, vol. 11, no. 3, pp. 309–317, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. R. L. Wright, E. N. Lightner, J. S. Harman, O. C. Meijer, and C. D. Conrad, “Attenuating corticosterone levels on the day of memory assessment prevents chronic stress-induced impairments in spatial memory,” European Journal of Neuroscience, vol. 24, no. 2, pp. 595–605, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. C. Tojo, T. Takao, T. Nishioka, Y. Numata, S. Suemaru, and K. Hashimoto, “Hypothalamic-pituitary-adrenal axis in WBN/Kob rats with non-insulin dependent diabetes mellitus,” Endocrine Journal, vol. 43, no. 2, pp. 233–239, 1996. View at Google Scholar · View at Scopus
  75. D. N. Alfarez, M. Joëls, and H. J. Krugers, “Chronic unpredictable stress impairs long-term potentiation in rat hippocampal CA1 area and dentate gyrus in vitro,” European Journal of Neuroscience, vol. 17, no. 9, pp. 1928–1934, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. V. Korz and J. U. Frey, “Stress-related modulation of hippocampal long-term potentiation in rats: involvement of adrenal steroid receptors,” Journal of Neuroscience, vol. 23, no. 19, pp. 7281–7287, 2003. View at Google Scholar · View at Scopus
  77. Y. Revsin, N. V. Rekers, M. C. Louwe et al., “Glucocorticoid receptor blockade normalizes hippocampal alterations and cognitive impairment in streptozotocin-induced type 1 diabetes mice,” Neuropsychopharmacology, vol. 34, no. 3, pp. 747–758, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. C. Messier, “Impact of impaired glucose tolerance and type 2 diabetes on cognitive aging,” Neurobiology of Aging, vol. 26, supplement, pp. S26–S30, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Desrocher and J. Rovet, “Neurocognitive correlates of type 1 diabetes mellitus in childhood,” Child Neuropsychology, vol. 10, no. 1, pp. 36–52, 2004. View at Publisher · View at Google Scholar · View at Scopus
  80. T. C. Sandeep, J. L. W. Yau, A. M. J. MacLullich et al., “11β-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 17, pp. 6734–6739, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. S. J. Lupien, F. Maheu, M. Tu, A. Fiocco, and T. E. Schramek, “The effects of stress and stress hormones on human cognition: implications for the field of brain and cognition,” Brain and Cognition, vol. 65, no. 3, pp. 209–237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. R. J. Anderson, K. E. Freedland, R. E. Clouse, and P. J. Lustman, “The prevalence of comorbid depression in adults with diabetes: a meta-analysis,” Diabetes Care, vol. 24, no. 6, pp. 1069–1078, 2001. View at Google Scholar · View at Scopus
  83. S. A. Everson, S. C. Maty, J. W. Lynch, and G. A. Kaplan, “Epidemiologic evidence on the comorbidity of depression and diabetes,” Journal of Psychosomatic Research, vol. 53, no. 4, pp. 903–906, 2002. View at Publisher · View at Google Scholar · View at Scopus
  84. M. J. Knol, J. W. R. Twisk, A. T. F. Beekman, R. J. Heine, F. J. Snoek, and F. Pouwer, “Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis,” Diabetologia, vol. 49, no. 5, pp. 837–845, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. C. Dufouil, R. Fuhrer, J.-F. Dartigues, and A. Alpérovitch, “Longitudinal analysis of the association between depressive symptomatology and cognitive deterioration,” American Journal of Epidemiology, vol. 144, no. 7, pp. 634–641, 1996. View at Google Scholar · View at Scopus
  86. G. W. Lambert, M. P. Schlaich, and M. D. Esler, “Brain derived neurotrophic factor (BDNF) release from the human brain in patients with type 2 diabetes - Possible influence of venous anatomy and comorbid major depressive disorder,” Diabetologia, vol. 50, no. 9, pp. 2027–2028, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. D. G. Bruce, G. Casey, W. A. Davis et al., “Vascular depression in older people with diabetes,” Diabetologia, vol. 49, no. 12, pp. 2828–2836, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. I. K. Lyoo, S. J. Yoon, G. Musen et al., “Altered prefrontal glutamate-glutamine-γ-aminobutyric acid levels and relation to low cognitive performance and depressive symptoms in type 1 diabetes mellitus,” Archives of General Psychiatry, vol. 66, no. 8, pp. 878–887, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. E. A. Northam, D. Rankins, A. Lin et al., “Central nervous system function in youth with type 1 diabetes 12 years after disease onset,” Diabetes Care, vol. 32, no. 3, pp. 445–450, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Kuhad, R. Sethi, and K. Chopra, “Lycopene attenuates diabetes-associated cognitive decline in rats,” Life Sciences, vol. 83, no. 3-4, pp. 128–134, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. R. Schmatz, C. M. Mazzanti, R. Spanevello et al., “Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats,” European Journal of Pharmacology, vol. 610, no. 1–3, pp. 42–48, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. G. Sánchez-Chávez and R. Salceda, “Effect of streptozotocin-induced diabetes on activities of cholinesterases in the rat retina,” IUBMB Life, vol. 49, no. 4, pp. 283–287, 2000. View at Google Scholar · View at Scopus
  93. A. Kamal, G.-J. Biessels, I. J. A. Urban, and W. H. Gispen, “Hippocampal synaptic plasticity in streptozotocin-diabetic rats: impairment of long-term potentiation and facilitation of long-term depression,” Neuroscience, vol. 90, no. 3, pp. 737–745, 1999. View at Publisher · View at Google Scholar · View at Scopus
  94. B. Valastro, J. Cossette, N. Lavoie, S. Gagnon, F. Trudeau, and G. Massicotte, “Up-regulation of glutamate receptors is associated with LTP defects in the early stages of diabetes mellitus,” Diabetologia, vol. 45, no. 5, pp. 642–650, 2002. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Wang, F. Fu, B. Han, L. Zhang, and X. Zhang, “Danshensu ameliorates the cognitive decline in streptozotocin-induced diabetic mice by attenuating advanced glycation end product-mediated neuroinflammation,” Journal of Neuroimmunology, vol. 245, no. 1-2, pp. 79–86, 2012. View at Publisher · View at Google Scholar · View at Scopus
  96. Y.-W. Liu, X. Zhu, Q. Lu et al., “Total saponins from Rhizoma Anemarrhenae ameliorate diabetes-associated cognitive decline in rats: involvement of amyloid-beta decrease in brain,” Journal of Ethnopharmacology, vol. 139, no. 1, pp. 194–200, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Fukuhara, K. Matsumura, M. Wakisaka et al., “Hyperglycemia promotes microinflammation as evaluated by C-reactive protein in the very elderly,” Internal Medicine, vol. 46, no. 5, pp. 207–212, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. R. A. Kowluru and M. Kanwar, “Effects of curcumin on retinal oxidative stress and inflammation in diabetes,” Nutrition and Metabolism, vol. 4, article 8, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. Y.-W. Liu, X. Zhu, W. Li et al., “Ginsenoside Re attenuates diabetes-associated cognitive deficits in rats,” Pharmacology Biochemistry and Behavior, vol. 101, no. 1, pp. 93–98, 2012. View at Publisher · View at Google Scholar · View at Scopus
  100. P. Bhutada, Y. Mundhada, K. Bansod et al., “Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes,” Behavioural Brain Research, vol. 220, no. 1, pp. 30–41, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Kuhad and K. Chopra, “Curcumin attenuates diabetic encephalopathy in rats: behavioral and biochemical evidences,” European Journal of Pharmacology, vol. 576, no. 1–3, pp. 34–42, 2007. View at Publisher · View at Google Scholar · View at Scopus
  102. M. S. Parihar, M. Chaudhary, R. Shetty, and T. Hemnani, “Susceptibility of hippocampus and cerebral cortex to oxidative damage in streptozotocin treated mice: prevention by extracts of Withania somnifera and Aloe vera,” Journal of Clinical Neuroscience, vol. 11, no. 4, pp. 397–402, 2004. View at Publisher · View at Google Scholar · View at Scopus
  103. A. Artola, “Diabetes-, stress- and ageing-related changes in synaptic plasticity in hippocampus and neocortex—the same metaplastic process?” European Journal of Pharmacology, vol. 585, no. 1, pp. 153–162, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. P. Reisi, S. Babri, H. Alaei, M. R. Sharifi, G. Mohaddes, and R. Lashgari, “Effects of treadmill running on short-term pre-synaptic plasticity at dentate gyrus of streptozotocin-induced diabetic rats,” Brain Research, vol. 1211, pp. 30–36, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. L. Ye, F. Wang, and R.-H. Yang, “Diabetes impairs learning performance and affects the mitochondrial function of hippocampal pyramidal neurons,” Brain Research, vol. 1411, pp. 57–64, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. H. Kalalian-Moghaddam, T. Baluchnejadmojarad, M. Roghani et al., “Hippocampal synaptic plasticity restoration and anti-apoptotic effect underlie berberine improvement of learning and memory in streptozotocin- diabetic rats,” European Journal of Pharmacology, vol. 698, pp. 259–266, 2013. View at Google Scholar
  107. E. Van Den Berg, Y. D. Reijmer, J. De Bresser, R. P. C. Kessels, L. J. Kappelle, and G. J. Biessels, “A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus,” Diabetologia, vol. 53, no. 1, pp. 58–65, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. J. Kuusisto, K. Koivisto, L. Mykkänen et al., “Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study,” British Medical Journal, vol. 315, no. 7115, pp. 1045–1049, 1997. View at Google Scholar · View at Scopus